| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6099599 | Journal of Crohn's and Colitis | 2013 | 10 Pages |
Abstract
This analysis suggests that moderate CD patients can be treated effectively with adalimumab, and supports using CRP to identify moderate CD patients at greatest risk of disease progression.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
William J. Sandborn, Jean-Frederic Colombel, Julian Panés, Majin Castillo, Anne M. Robinson, Qian Zhou, Mei Yang, Roopal Thakkar,